SK281982B6 - Použitie zlúčenín gabapentínu na výrobu liečiva - Google Patents

Použitie zlúčenín gabapentínu na výrobu liečiva Download PDF

Info

Publication number: SK281982B6
Authority: SK; Slovakia
Prior art keywords: treatment; mania; medicament; manufacture; gabapentin
Prior art date: 1995-05-15

Application number

SK1528-97A

Other languages

English (en)

Slovak (sk)

Other versions

SK152897A3 (en

Inventor

Atul Chandra Pande

Original Assignee

Warner-Lambert Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-05-15

Filing date

1996-04-26

Publication date

2001-09-11

1996-04-26 Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company

1999-05-07 Publication of SK152897A3 publication Critical patent/SK152897A3/sk

2001-09-11 Publication of SK281982B6 publication Critical patent/SK281982B6/sk

Links

206010026749 Mania Diseases 0.000 title claims abstract description 18
208000020925 Bipolar disease Diseases 0.000 title claims abstract description 11
UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical class OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims abstract description 24
239000003814 drug Substances 0.000 claims abstract description 10
238000004519 manufacturing process Methods 0.000 claims abstract description 8
150000003839 salts Chemical class 0.000 claims abstract description 8
125000000217 alkyl group Chemical group 0.000 claims abstract description 6
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 4
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 4
239000001257 hydrogen Substances 0.000 claims abstract description 4
230000002265 prevention Effects 0.000 claims abstract description 4
208000024891 symptom Diseases 0.000 claims abstract description 4
229960002870 gabapentin Drugs 0.000 claims description 8
241000124008 Mammalia Species 0.000 claims description 3
230000001684 chronic effect Effects 0.000 claims description 2
-1 gabapentin compound Chemical class 0.000 claims description 2
230000000306 recurrent effect Effects 0.000 claims description 2
150000001875 compounds Chemical class 0.000 description 16
230000000694 effects Effects 0.000 description 6
239000000203 mixture Substances 0.000 description 5
206010015037 epilepsy Diseases 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
206010010904 Convulsion Diseases 0.000 description 3
206010022998 Irritability Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
230000009286 beneficial effect Effects 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
208000019901 Anxiety disease Diseases 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
201000010099 disease Diseases 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000003340 mental effect Effects 0.000 description 2
208000015122 neurodegenerative disease Diseases 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
MXNASYICBPHSLF-UHFFFAOYSA-N 2-[1-(aminomethyl)cycloheptyl]acetic acid Chemical compound OC(=O)CC1(CN)CCCCCC1 MXNASYICBPHSLF-UHFFFAOYSA-N 0.000 description 1
MKGSCDBHUPQQMX-UHFFFAOYSA-N 2-[1-(aminomethyl)cyclopentyl]acetic acid Chemical compound OC(=O)CC1(CN)CCCC1 MKGSCDBHUPQQMX-UHFFFAOYSA-N 0.000 description 1
LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
206010001488 Aggression Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
206010003497 Asphyxia Diseases 0.000 description 1
208000014644 Brain disease Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
206010013496 Disturbance in attention Diseases 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
206010019196 Head injury Diseases 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
208000006083 Hypokinesia Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
208000019022 Mood disease Diseases 0.000 description 1
206010029216 Nervousness Diseases 0.000 description 1
208000027626 Neurocognitive disease Diseases 0.000 description 1
241000907646 Newmania Species 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
206010038743 Restlessness Diseases 0.000 description 1
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
GAMPNQJDUFQVQO-UHFFFAOYSA-N acetic acid;phthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O GAMPNQJDUFQVQO-UHFFFAOYSA-N 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
208000012761 aggressive behavior Diseases 0.000 description 1
230000016571 aggressive behavior Effects 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
230000006399 behavior Effects 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
230000003925 brain function Effects 0.000 description 1
208000029028 brain injury Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
230000019771 cognition Effects 0.000 description 1
239000003086 colorant Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
PQCNPWAMVMHDID-UHFFFAOYSA-N ethyl 2-[1-(aminomethyl)cyclohexyl]acetate Chemical compound CCOC(=O)CC1(CN)CCCCC1 PQCNPWAMVMHDID-UHFFFAOYSA-N 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
230000006870 function Effects 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
230000003483 hypokinetic effect Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
206010022437 insomnia Diseases 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
208000024714 major depressive disease Diseases 0.000 description 1
239000000463 material Substances 0.000 description 1
230000006993 memory improvement Effects 0.000 description 1
BPUUTTKHBSNDRT-UHFFFAOYSA-N methyl 2-[1-(aminomethyl)cycloheptyl]acetate Chemical compound COC(=O)CC1(CN)CCCCCC1 BPUUTTKHBSNDRT-UHFFFAOYSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
230000036651 mood Effects 0.000 description 1
230000037023 motor activity Effects 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
208000019906 panic disease Diseases 0.000 description 1
239000003182 parenteral nutrition solution Substances 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000002636 symptomatic treatment Methods 0.000 description 1
206010042772 syncope Diseases 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229960004559 theobromine Drugs 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000008733 trauma Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
230000036642 wellbeing Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Psychiatry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Emergency Medicine (AREA)
Organic Chemistry (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Beans For Foods Or Fodder (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pyridine Compounds (AREA)
Indole Compounds (AREA)
Saccharide Compounds (AREA)

SK1528-97A 1995-05-15 1996-04-26 Použitie zlúčenín gabapentínu na výrobu liečiva SK281982B6 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/440,570 US5510381A (en)	1995-05-15	1995-05-15	Method of treatment of mania and bipolar disorder
PCT/US1996/005898 WO1996036328A1 (en)	1995-05-15	1996-04-26	A method of treatment of mania and bipolar disorder

Publications (2)

Publication Number	Publication Date
SK152897A3 SK152897A3 (en)	1999-05-07
SK281982B6 true SK281982B6 (sk)	2001-09-11

Family

ID=23749281

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1528-97A SK281982B6 (sk)	1995-05-15	1996-04-26	Použitie zlúčenín gabapentínu na výrobu liečiva

Country Status (19)

Country	Link
US (1)	US5510381A (no)
EP (1)	EP0825857B1 (no)
JP (1)	JPH11505244A (no)
AT (1)	ATE218857T1 (no)
AU (1)	AU702435B2 (no)
CA (1)	CA2215923C (no)
CZ (1)	CZ288072B6 (no)
DE (1)	DE69621799T2 (no)
DK (1)	DK0825857T3 (no)
EE (1)	EE03420B1 (no)
ES (1)	ES2177783T3 (no)
GE (1)	GEP20002014B (no)
HU (1)	HUP9802087A3 (no)
NO (1)	NO315967B1 (no)
NZ (1)	NZ307366A (no)
PT (1)	PT825857E (no)
SK (1)	SK281982B6 (no)
WO (1)	WO1996036328A1 (no)
ZA (1)	ZA963826B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6372792B1 (en)	1996-04-26	2002-04-16	Guy Chouinard	Method for treating anxiety, anxiety disorders and insomnia
IL126999A (en)	1996-07-24	2002-03-10	Warner Lambert Co	Pharmaceutical preparations containing isobutylgaba and its history for use in the treatment of pain
AU9318398A (en)	1997-10-07	1999-04-27	Warner-Lambert Company	Process for preparing a cyclic amino acid anticonvulsant compound
US6635673B1 (en)	1997-10-27	2003-10-21	Warner-Lambert Company	Cyclic amino acids and derivatives thereof useful as pharmaceutical agents
WO1999059572A1 (en) *	1998-05-15	1999-11-25	Warner-Lambert Company	Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same
WO1999059573A1 (en)	1998-05-15	1999-11-25	Warner-Lambert Company	Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same
AU757445B2 (en)	1998-05-26	2003-02-20	Warner-Lambert Company	Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel
BR9911887A (pt) *	1998-07-09	2001-03-27	Warner Lambert Co	Método para o tratamento da insÈnia
DK1121114T3 (da) *	1998-10-16	2007-04-10	Warner Lambert Co	Anvendelse af GABA-analoger til fremstilling af et medikament til behandling af mani og bipolære lidelser
EP1187832B1 (en) *	1999-06-02	2002-11-20	Warner-Lambert Company	Amino heterocycles useful as pharmaceutical agents
AP2002002501A0 (en) *	1999-10-07	2002-06-30	Warner Lambert Co	Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog.
EP1294364A4 (en) *	2000-06-16	2004-06-16	Teva Pharma	STABLE GABAPENTINE WITH A PH WITHIN A CONTROLLED AREA
BR0111913A (pt) *	2000-06-26	2004-01-06	Warner Lambert Co	Análogos de gabapentina para distúrbios do sono
ITMI20012750A1 (it)	2001-12-21	2003-06-21	Procos Spa	Processo per la produzione dell'acido 1-(amminometil)-cicloesil-acetico in forma pura
US20030119908A1 (en) *	2001-12-21	2003-06-26	Zambon Group S.P.A.	Stable gabapentin compositions
CA2451267A1 (en) *	2002-12-13	2004-06-13	Warner-Lambert Company Llc	Pharmaceutical uses for alpha2delta ligands
WO2011151708A1 (en)	2010-06-01	2011-12-08	Rubicon Research Private Limited	Gastroretentive dosage forms of gaba analogs
EP2923694B1 (en)	2014-03-27	2018-11-14	Sanovel Ilac Sanayi ve Ticaret A.S.	Oral liquid pharmaceutical solution of gabapentin
US11670410B1 (en) *	2022-04-13	2023-06-06	Green Sky Creations LLC	Systems and methods to automatically administer a psychoactive substance to an airway of a user based on a detected event or condition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2460891C2 (de) *	1974-12-21	1982-09-23	Gödecke AG, 1000 Berlin	1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) *	1974-12-21	1978-05-02	Warner-Lambert Company	Treatment of cranial dysfunctions using novel cyclic amino acids
US4355044A (en) *	1980-12-19	1982-10-19	Bernardo Heller	D-Phenylalanine treatment
US5084479A (en) *	1990-01-02	1992-01-28	Warner-Lambert Company	Novel methods for treating neurodegenerative diseases
US5086072A (en) *	1990-06-18	1992-02-04	The United States Of America As Represented By The Department Of Health And Human Services	Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
US5025035A (en) *	1990-10-12	1991-06-18	Warner-Lambert Company	Method of treating depression

1995
- 1995-05-15 US US08/440,570 patent/US5510381A/en not_active Expired - Fee Related
1996
- 1996-04-26 ES ES96913852T patent/ES2177783T3/es not_active Expired - Lifetime
- 1996-04-26 WO PCT/US1996/005898 patent/WO1996036328A1/en active IP Right Grant
- 1996-04-26 JP JP8534854A patent/JPH11505244A/ja not_active Ceased
- 1996-04-26 EP EP96913852A patent/EP0825857B1/en not_active Expired - Lifetime
- 1996-04-26 SK SK1528-97A patent/SK281982B6/sk unknown
- 1996-04-26 CA CA002215923A patent/CA2215923C/en not_active Expired - Fee Related
- 1996-04-26 AT AT96913852T patent/ATE218857T1/de not_active IP Right Cessation
- 1996-04-26 DK DK96913852T patent/DK0825857T3/da active
- 1996-04-26 AU AU56689/96A patent/AU702435B2/en not_active Ceased
- 1996-04-26 GE GEAP19964027A patent/GEP20002014B/en unknown
- 1996-04-26 HU HU9802087A patent/HUP9802087A3/hu unknown
- 1996-04-26 PT PT96913852T patent/PT825857E/pt unknown
- 1996-04-26 CZ CZ19973558A patent/CZ288072B6/cs not_active IP Right Cessation
- 1996-04-26 NZ NZ307366A patent/NZ307366A/en unknown
- 1996-04-26 DE DE69621799T patent/DE69621799T2/de not_active Expired - Fee Related
- 1996-04-26 EE EE9700302A patent/EE03420B1/xx not_active IP Right Cessation
- 1996-05-14 ZA ZA963826A patent/ZA963826B/xx unknown
1997
- 1997-11-14 NO NO19975234A patent/NO315967B1/no unknown

Also Published As

Publication number	Publication date
DE69621799T2 (de)	2003-01-02
HUP9802087A3 (en)	1999-08-30
CZ355897A3 (cs)	1998-02-18
NO975234D0 (no)	1997-11-14
US5510381A (en)	1996-04-23
MX9707269A (es)	1997-11-29
EE03420B1 (et)	2001-06-15
ES2177783T3 (es)	2002-12-16
CA2215923C (en)	2001-10-09
EE9700302A (et)	1998-06-15
NO315967B1 (no)	2003-11-24
DK0825857T3 (da)	2002-09-30
NZ307366A (en)	1999-10-28
PT825857E (pt)	2002-11-29
ZA963826B (en)	1996-11-21
ATE218857T1 (de)	2002-06-15
NO975234L (no)	1997-11-14
DE69621799D1 (de)	2002-07-18
EP0825857A1 (en)	1998-03-04
EP0825857B1 (en)	2002-06-12
AU702435B2 (en)	1999-02-18
WO1996036328A1 (en)	1996-11-21
AU5668996A (en)	1996-11-29
JPH11505244A (ja)	1999-05-18
HUP9802087A2 (hu)	1998-12-28
CZ288072B6 (cs)	2001-04-11
SK152897A3 (en)	1999-05-07
GEP20002014B (en)	2000-04-10
CA2215923A1 (en)	1996-11-21

Publication	Publication Date	Title
SK281982B6 (sk)	2001-09-11	Použitie zlúčenín gabapentínu na výrobu liečiva
EP1121114B1 (en)	2007-01-10	Use of gaba analogs for the manufacture of a medicament for the treatment of mania and bipolar disorders
HUE033180T2 (en)	2017-11-28	Peptide compounds for the treatment of difficult to cure epileptic diseases
JP3192141B2 (ja)	2001-07-23	抗うつ剤
US5011841A (en)	1991-04-30	Treatment of depression
US4906649A (en)	1990-03-06	Use of a compound for the treatment of sleep disorders and depression
EP0615750A2 (en)	1994-09-21	Treatment of a group of related disorders
DE19929065A1 (de)	2000-12-28	Kombination von MTP-Inhibitoren und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
MXPA97007269A (en)	1998-07-03	A method of treatment of mania and disorderbipo
DE3136455C2 (de)	1984-09-13	Verwendung von Caerulein oder dessen pharmazeutisch verträglichen Salzen bei der Bekämpfung von psychotischen Krankheitszuständen
BG63379B1 (bg)	2001-12-29	Метод за лечение на маниакално и двуполюсно заболяване
US2775539A (en)	1956-12-25	Process of and compositions for combating epileptic seizures with atrolactamide
DE19929012A1 (de)	2000-12-28	Kombination von MTP-Inhibitoren und stoffwechselbeeinflussenden Wirkstoffen und ihre Verwendung in Arzneimitteln
EP0347927A2 (de)	1989-12-27	Verwendung von 2-Phenyl-1,2-benzisoselenazol-3(2H)-on (Ebselen) zur Herstellung von Arzneimitteln zur Behandlung von Malaria
US3380887A (en)	1968-04-30	Use of butyrolactam for treating motion sickness
EP0398171A2 (de)	1990-11-22	Verwendung von Imidazodiazepinen bei der Behandlung von neurologischen Symptomen, welche mit zirkulatorischen Störungen des Gehirns assoziiert sind
JPH0586043A (ja)	1993-04-06	医薬組成物